Detection of Novel apyrimidinic Endonuclease 1 (APE1) in a sample of Iraqi cervical cancer patients using Immunohistochemistry Technique

Yasser Kadhim Hashem Al-Zwaini; Suhad Faisal Hatem Al-Mugdadi; Wassan Abdul Kareem Abbas

doi:10.5958/0974-360X.2020.00565.X

Research Journal of Pharmacy and Technology

ISSN

0974-360X (Online)
0974-3618 (Print)

Submit Article

Detection of Novel apyrimidinic Endonuclease 1 (APE1) in a sample of Iraqi cervical cancer patients using Immunohistochemistry Technique

Author(s): Yasser Kadhim Hashem Al-Zwaini, Suhad Faisal Hatem Al-Mugdadi, Wassan Abdul Kareem Abbas

Email(s): suhadhatim@uomustansiriyah.edu.iq /orcid.org

DOI: 10.5958/0974-360X.2020.00565.X

Address: Yasser Kadhim Hashem Al-Zwaini1, Suhad Faisal Hatem Al-Mugdadi2, Wassan Abdul Kareem Abbas2
1Al-Esraa University College, Iraq.
2Mustansiriyah University, College of Pharmacy, Department of Clinical Laboratories Sciences, Iraq.
*Corresponding Author

Published In: Volume - 13, Issue - 7, Year - 2020

View HTML

View PDF

ABSTRACT:
Objective: to identify the expression of DNA repair protein apyrimidinic endonuclease 1 (APE1) in samples of Iraqi cervical cancer patients. Method: expression of APE1 was detected in 55 cervical tissue samples by immunohistochemistry, divided into two groups; 35 cases detected as invasive cervical cancer and 20 cases considered as control. Immunohistochemistry was achieved and the nuclear and cytoplasm-nuclear level of APE1 was counted by taking into account the ratio of positive cells and intensity. Results: Present data evaluated the prognostic and alterations in APE1 expression levels according to cervical cancer, nuclear stain was seen in the epithelia of 35 cases (100 %) of cervical tumor tissues. Only 29 out of 35 cases (82.85 %) shown cytoplasmic and nuclear staining with significant difference (P value = 0.00027) between malignant and normal cervical tissue. APE1 high-level expression was (77.1%) and low expression was (22.8 %) in cervical cancer tissues. Age, differentiation and histologic type showed highly significant difference (P= 0.0062, 0.0001 and 0.0001 respectively) between the high and low expression of nuclear APEX1 expression. While lymph vascular invasion (positive vs negative group) showed a significant difference (Chi-Square 4.362, P value = 0.0422*) between the high (16/59.2%) and low (4/50%) nuclear expression of APEX1, while lymph node (positive vs negative group) showed no significant association (P-value= 0.1476) between the high and low expression of nuclear APEX1. Conclusion: The highly positive expression of APE1 results will help Iraqi patients in their early investigation and diagnosis of cervical cancer as good marker for the metastases of their tumor and help researchers to study the lymphangiogensis status of tumor.

Keywords:

Cite this article:
Yasser Kadhim Hashem Al-Zwaini, Suhad Faisal Hatem Al-Mugdadi, Wassan Abdul Kareem Abbas. Detection of Novel apyrimidinic Endonuclease 1 (APE1) in a sample of Iraqi cervical cancer patients using Immunohistochemistry Technique. Research J. Pharm. and Tech. 2020; 13(7): 3193-3198. doi: 10.5958/0974-360X.2020.00565.X

Cite(Electronic):
Yasser Kadhim Hashem Al-Zwaini, Suhad Faisal Hatem Al-Mugdadi, Wassan Abdul Kareem Abbas. Detection of Novel apyrimidinic Endonuclease 1 (APE1) in a sample of Iraqi cervical cancer patients using Immunohistochemistry Technique. Research J. Pharm. and Tech. 2020; 13(7): 3193-3198. doi: 10.5958/0974-360X.2020.00565.X Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-7-25

REFERENCES:

1. Ibrahim A, Rasch V, Pukkala E, Aro AR. Cervical cancer risk factors and feasibility of visual inspection with acetic acid screening in Sudan. International Journal of Women's Health. 2011; 3:117.

2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. The Lancet. 2007; 370(9590): 890-907.

3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Meeting, World Health Organization, International Agency for Research on Cancer. Human papillomaviruses. World Health Organization; 2007.

4. Castle PE. How does tobacco smoke contribute to cervical carcinogenesis?. Journal of virology. 2008 Jun 15;82(12):6084-6.

5. Munoz N, Castellsagué X, de González AB, GissmannL. HPV in the etiology of human cancer. Vaccine. 2006;24: S1-0.

6. Kahn JA, Lan Dand Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstetrics and Gynecology. 2007;110(1):87-95.

7. World Health Organization. Cervical cancer: estimated incidence, mortality and prevalence worldwide in 2012. Archived at: http://www. webcitation. org/6zIbaJC1q. 2017.

8. Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Iraq. Summary Report 17 June 2019.

9. Xanthoudakis S, Curran T. Identification and characterization of Ref‐1, a nuclear protein that facilitates AP‐1 DNA‐binding activity. The EMBO journal. 1992 Feb;11(2):653-65.

10. Robson CN, Hickson ID. Isolation of cDNA clones encoding a humanapurini/apyrimidinic endonuclease that corects DNA repair and mutagenisis defects in E. coli xth (exonuclease III) mutants. Nucleic acids research. 1991;19(20):5519-23.

11. Demple B, Herman T, Chen DS. Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes. Proceedings of the National Academy of Sciences. 1991;88(24):11450-4.

12. Li M, Wilson DM, 3rd. Human apurinic/apyrimidinicendonuclease 1. Antioxid Redox Signal. 2014; 20:678–707.

13. Robson CN, Hickson ID. Isolation of cDNA clones encoding a human apurini/apyrimidinic endonuclease that corects DNA repair and mutagenisis defects in E. coli xth (exonuclease III) mutants. Nucleic acids research. 1991;19(20):5519-23.

14. Robson CN, Hochhauser D, Craig R, Rack K, Bukie VJ, Hickson ID. Structure of the human DNA repair gene HAP1 and its localisation to chromosome 14q 11.2–12. Nucleic acids research. 1992;20 (17):4417-21.

15. Xanthoudakis S, Miao GG, Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proceedings of the National Academy of Sciences. 1994;91(1):23-7.

16. Tell G, Damante G, Caldwell D, Kelley MR. The intracellular localization of APE1/Ref-1: more than a passive phenomenon?. Antioxidants and Redox Signaling. 2005;7(3-4):367-84.

17. Woo J, Park H, Sung SH, Moon BI, Suh H, Lim W. Prognostic value of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in breast cancer. PloS one. 2014;9(6):e99528.

18. Abbotts R, Madhusudan S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treatment Reviews. 2010;36(5):425-35.

19. Wei X, Li YB, Li Y, Lin BC, Shen XM, Cui RL, Gu YJ, Gao M, Li YG, Zhang S. Prediction of lymph node metastases in gastric cancer by serum APE1 expression. Journal of Cancer. 2017; 8(8):1492.

20. Zhang S, He L, Dai N, Guan W, Shan J, Yang X, Zhong Z, Qing Y, Jin F, Chen C, Yang Y. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients. Oncotarget. 2016;7(47):77482.

21. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Molecular Cancer Therapeutics. 2004;3(6):679-86.

22. Kakolyris S, Giatromanolaki A, Koukourakis M, Kaklamanis L, Kanavaros P, Hickson ID, Barzilay G, Georgoulias V, Gatter KC, Harris AL. Nuclear localization of human AP endonuclease 1 (HAP1/Ref‐1) associates with prognosis in early operable non‐small cell lung cancer (NSCLC). The Journal of Pathology. 1999 Nov;189(3):351-7.

23. Puglisi F, Barbone F, Tell G, Aprile G, Pertoldi B, Raiti C, Kelley MR, Damante G, Sobrero A, Beltrami CA, Di Loreto C. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncology Reports. 2002;9(1):11-7.

24. Koukourakis MI, Giatromanolaki A, Kakolyris S, Sivridis E, Georgoulias V, Funtzilas G, Hickson I D, Gatter KC, Harris AL. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. International Journal of Radiation Oncology Biology Physics. 2001;50(1):27-36.

25. Robertson KA, Bullock HA, Xu Y, Tritt R, Zimmerman E, UlbrightTM, Foster RS, Einhorn LH, Kelley MR. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Research. 2001;61(5):2220-5.

26. Al-Attar A, Gossage L, Fareed KR, Shehata M, Mohammed M, Zaitoun AM, SoomroI, Lobo DN, Abbotts R, Chan S, MadhusudanS. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. British Journal of Cancer. 2010; 102(4): 704.

27. Wei X, Li Q, Li Y, Duan W, Huang C, Zheng X, Sun L, Luo J, Wang D, Zhang S, Xin X. Prediction of survival prognosis of non-small cell lung cancer by APE1 through regulation of Epithelial-Mesenchymal Transition. Oncotarget. 2016;7(19):28523.

28. Tell G, Damante G, Caldwell D, Kelley MR. The intracellular localization of APE1/Ref-1: more than a passive phenomenon?. Antioxidants and Redox Signaling. 2005;7(3-4):367-84.

29. Puglisi F, Barbone F, Tell G, Aprile G, Pertoldi B, Raiti C, Kelley MR, Damante G, Sobrero A, Beltrami CA, Di Loreto C. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncology Reports. 2002;9(1):11-7.

30. Kakolyris S, Kaklamanis L, Engels K, Fox SB, Taylor M, Hickson ID, Gatter KC, Harris AL. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. British Journal of Cancer. 1998; 77(7): 1169.

31. Di Maso V, Avellini C, Croce LS, Rosso N, Quadrifoglio F, et al. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med .2007;13: 89–96.

32. Shin JH, Choi S, Lee YR, Park MS, Na YG, Irani K, Do Lee S, Park JB, Kim JM, Lim JS, Jeon BH. APE1/Ref-1 as a serological biomarker for the detection of bladder cancer. Cancer research and treatment: Official Journal of Korean Cancer Association. 2015; 47(4): 823.

33. Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer. 2009;66 (3):298-304.